Der Nervenarzt

, Volume 81, Issue 8, pp 1003–1006

Intrathekale Baclofen-Therapie bei gehfähigen Patienten mit spastischer Hemiparese nach Schlaganfall

Kurzer Bericht zweier Fälle
Briefe an die Herausgeber

Intrathecal baclofen therapy in ambulatory patients with spastic hemiparesis following stroke

Short report of two cases


  1. 1.
    Albright AL (1996) Baclofen in the treatment of cerebral palsy. J Child Neurol 11:77–83CrossRefPubMedGoogle Scholar
  2. 2.
    Becker R, Alberti O, Bauer BL (1997) Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. J Neurol 244:160–166CrossRefPubMedGoogle Scholar
  3. 3.
    Brashear A, Gordon MF, Elovic E et al (2002) Botox post-stroke spasticity study group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. N Engl J Med 347:395–400CrossRefPubMedGoogle Scholar
  4. 4.
    Coffrey RJ, Cahill D, Steers W et al (1993) Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 78:226–232CrossRefGoogle Scholar
  5. 5.
    Formisano R, Pantano P, Buzzi G et al (2005) Late motor recovery is influenced by muscle tone changes after stroke. Arch Phys Med Rehabil 86:308–311CrossRefPubMedGoogle Scholar
  6. 6.
    Francisco G (2007) Intrathecal baclofen in the management of post-stroke hypertonia: current applications and future directions. Acta Neurochir Suppl 97:219–226CrossRefPubMedGoogle Scholar
  7. 7.
    Francisco G, Boake C (2003) Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: A preliminary study. Arch Med Rehabil 84:1194–1199CrossRefGoogle Scholar
  8. 8.
    Gerszten PC, Albright AL, Barry MJ (1997) Effect on ambulation of continuous baclofen infusion. Pediatr Neurosurg 27:40–44CrossRefPubMedGoogle Scholar
  9. 9.
    Ivanhoe C, Francisco G, McGuire J et al (2006) Intrathecal baclofen management of poststroke spastic hypertonia: Implications for function and quality of life. Arch Phys Med Rehabil 87:1509–1515CrossRefPubMedGoogle Scholar
  10. 10.
    Kofler M, Qirbach E, Schauer R et al (2009) Limitations of intrathecal baclofen for spastic hemiparesis following stroke. Neurorehabil Neural Repair 23:26–31PubMedGoogle Scholar
  11. 11.
    Kroin JS, Penn RD (1991) Cerebrospinal fluid pharmacokinetics of lumbar intrathecal baclofen. In: Lakke JPWF, Delhaas EM, Ruttgers AWF (eds) Parenteral drug therapy in spasticity and Parkinson’s disease. Parthenon Publishing, Carnforth UK, pp 73–83Google Scholar
  12. 12.
    Montane E, Vallano A, Laporte JR (2004) Oral antispastic drugs in non-progressive neurologic diseases: a systematic review. Neurology 63(8):1357–1363PubMedGoogle Scholar
  13. 13.
    Meythaler J, DeVivo MJ, Hadley M (1996) Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to aquired brain injury. Arch Phys Med Rehabil 77:461–466CrossRefPubMedGoogle Scholar
  14. 14.
    Meythaler J, Guin-Renfroe S, Hadley M (1999) Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia. Am J Phys Med Rehabil 78:247–254CrossRefPubMedGoogle Scholar
  15. 15.
    Meythaler J, Guin-Renfroe S, Brunner R et al (2001) Intrathecal baclofen of spastic hypertonia from stroke. Stroke 32:2099–2109CrossRefPubMedGoogle Scholar
  16. 16.
    Penn RD, Savoy SM, Corcos DM et al (1989) Intrathecal baclofen for severe spinal spasticity. N Engl J Med 320:1517–1522CrossRefPubMedGoogle Scholar
  17. 17.
    Rémy-Néris O, Tiffreau V, Bouilland S, Bussel B (2003) Intrathecal baclofen in subjects with spastic hemiplegia: Assesment of antispastic effect during gait. Arch Phys Med Rehabil 84:643–650CrossRefPubMedGoogle Scholar
  18. 18.
    Sadiq S, Wang G (2006) Long-term intrathecal baclofen therapy in ambulatory patients with spasticity. J Neurol 253:563–569CrossRefPubMedGoogle Scholar
  19. 19.
    Saltuari L, Kronenberg M, Marosi M et al (1992) Long-term intrathecal baclofen treatment for supraspinal spasticity. Acta Neurol 47:195–207Google Scholar
  20. 20.
    Simpson DM, Alexander DN, O’Brian CF et al (1996) Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 46:1306–1310PubMedGoogle Scholar
  21. 21.
    Taricco M, Pagliacci MC, Telaro E, Adone R (2006) Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review. Eura Medicophys 42:5–15PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Abteilung für NeurochirurgieKlinikum KasselKasselDeutschland

Personalised recommendations